NOXXON Pharma N.V. announced that Bryan Jennings will join NOXXON as Chief Financial Officer (CFO) effective as of November 1, 2021. Mr. Jennings has over 30 years of experience in investment banking, capital raising and corporate finance advisory work, a significant amount of which has been in the healthcare, pharmaceutical and biotech sectors. Bryan brings with him extensive financial experience in the biotech industry with significant skills in capital raising and corporate finance. He will be a real asset for NOXXON as look to increasingly target investors in the US and progress the company financially, while continuing to focus on improving cancer treatments through unique approach of targeting the tumor microenvironment. Bryan Jennings has been CFO at a number of biotech and healthcare companies, including Peptilogics, KAHR Bio, Beren Therapeutics, Rational Vaccines and ChemomAb, where he was responsible for strategy and oversaw all financial, accounting, HR and IR functions. Additionally, he was CFO and CEO at Vista Capital Advisors, a broker dealer based in New York, NY. Prior to this, Mr. Jennings spent 20 years at Morgan Stanley where he was Managing Director, Head of Capital Markets and Risk Management.